Commensal obligate anaerobic bacteria and health: production, storage, and delivery strategies by Andrade, José Carlos et al.
REVIEW
published: 05 June 2020
doi: 10.3389/fbioe.2020.00550
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org 1 June 2020 | Volume 8 | Article 550
Edited by:
Eduardo Jacob-Lopes,




University of Granada, Spain
John MacSharry,




†These authors have contributed




LAQV, REQUIMTE, Departamento de
Ciências Químicas, Faculdade de
Farmácia, Universidade do Porto,
Porto, Portugal
Specialty section:
This article was submitted to
Bioprocess Engineering,
a section of the journal
Frontiers in Bioengineering and
Biotechnology
Received: 23 March 2020
Accepted: 07 May 2020
Published: 05 June 2020
Citation:
Andrade JC, Almeida D, Domingos M,
Seabra CL, Machado D, Freitas AC
and Gomes AM (2020) Commensal
Obligate Anaerobic Bacteria and
Health: Production, Storage, and
Delivery Strategies.
Front. Bioeng. Biotechnol. 8:550.
doi: 10.3389/fbioe.2020.00550
Commensal Obligate Anaerobic
Bacteria and Health: Production,
Storage, and Delivery Strategies
José Carlos Andrade 1†, Diana Almeida 2†, Melany Domingos 2, Catarina Leal Seabra 2‡,
Daniela Machado 2, Ana Cristina Freitas 2* and Ana Maria Gomes 2
1CESPU, Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde, Gandra, Portugal,
2CBQF - Centro de Biotecnologia e Química Fina - Laboratório Associado, Escola Superior de Biotecnologia, Universidade
Católica Portuguesa, Porto, Portugal
In the last years several human commensals have emerged from the gut microbiota
studies as potential probiotics or therapeutic agents. Strains of human gut inhabitants
such as Akkermansia, Bacteroides, or Faecalibacterium have shown several interesting
bioactivities and are thus currently being considered as food supplements or as
live biotherapeutics, as is already the case with other human commensals such as
bifidobacteria. The large-scale use of these bacteria will pose many challenges and
drawbacks mainly because they are quite sensitive to oxygen and/or very difficult
to cultivate. This review highlights the properties of some of the most promising
human commensals bacteria and summarizes the most up-to-date knowledge on their
potential health effects. A comprehensive outlook on the potential strategies currently
employed and/or available to produce, stabilize, and deliver these microorganisms is
also presented.
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INTRODUCTION
In the last years the knowledge about the human microbiota and its role in health and disease
has advanced considerably. This advance has revived the interest on the use of naturally occurring
bacteria from the human gut as therapeutic agents or as probiotics. Lactobacilli and bifidobacteria
have already a tradition of use in dietary or pharmaceutical forms and technologically robust strains
have been isolated and are produced industrially. However, the human gut microbiota studies have
highlighted other species of commensals which are consistently under-represented in different
disease conditions. Commensal bacteria such as Akkermansia and Faecalibacterium have been
shown to exert relevant bioactivities, mainly in cell and animalmodels, andmay be considered next-
generation probiotics or live therapeutic products (O’Toole et al., 2017). While several important
aspects such as effectiveness, safety, physiological, genomic, and metabolomics characteristics
still need to be completely understood, before a practical application can be put in place, other
overlooked aspects such as the production, storage stability, and delivery must also be investigated
(Jimenez et al., 2019). The latter aspects are extremely important to be explored as the commensal
microorganisms are usually strict anaerobes posing immediate challenges associated therewith.
In this review we summarize the current knowledge on the different strategies to produce,
stabilize, and deliver anaerobic commensals with special emphasis on the associated impact on
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stability and biological activity. Some of the most promising
human commensals are presented and their potential health
effects are discussed.
HUMAN GUT MICROBIOTA, DYSBIOSIS
AND THE NEED FOR PROBIOTICS
Humans are a complex organization of bacterial and human
cells that make up cellular communities, tissues, and functional
organs. This elaborate organism formed by human beings and the
inhabitantmicrobiota is defined as holobiont (Postler andGhosh,
2017; van de Guchte et al., 2018). These bacterial communities
residing at various ecological niches are an integrated part of
our biological system, in particular the gastrointestinal tract.
The gut microbiome is a dynamic and balanced assembly of
microorganisms and the resultant products of their collective
genetic and metabolic materials. They play an array of biological
functions ranging from controlling gut-immune system axis,
providing several key metabolites and maintaining an optimal
digestive system (Cani, 2018). With the advent of metagenomic
technologies, society is acknowledging the extreme influence
these microorganisms have on human health and disease
prevention, and the disturbance of their composition has been
implicated, over the years, in an assortment of pathologies (Neef
and Sanz, 2013). Indeed, to properly perform its functions, the
gut microbiota community must reveal a diverse, balanced and
stable composition, just like a perfectly in-tune orchestra, a
healthy state defined as “eubiosis” (Figure 1) (Iebba et al., 2016).
Unfortunately, this intricate bionetwork can be disturbed, a state
FIGURE 1 | Graphical summary of probiotic impact in gut epithelium of host. SCFAs - Short chain fatty acids; GPCR - G-protein coupled receptors.
defined as “dysbiosis,” which is a disruption in the mutually
beneficial relationship between a host and its microbiota leading
to the manifestation or progress of a specific disease (Figure 1)
(Singh et al., 2016).
This instability is usually not able to be attributed to a
single strain and is characterized mainly by the restriction of
bacterial diversity, with a decline in beneficial bacterial strains
abundance and a parallel increase of pathogenic bacteria and
this transition from the healthy state to dysbiosis involves stimuli
such as diet, host genetics, infection, or inflammation (Figure 1)
(Levy et al., 2017). Clinically, dysbiosis has been implicated
in pathogenesis of several intra and extra-intestinal diseases,
including inflammatory bowel disease, allergy, asthma, metabolic
syndrome, cardiovascular disease, and obesity (Carding et al.,
2015). Indeed, healthier dietary patterns, such as the increased
consumption of fibers, fermented foods and vegetables and
reduced consumption of saturated fats, have been linked with
higher diversity and the manipulation of such parameter leads
to compositional and functional shifts in intestinal microbiota,
ultimately correlating with diverse health outcomes (Wu et al.,
2011; Dao et al., 2016b). This being said, compliance to
such dietary recommendations by the general population is
known to be suboptimal (Krebs-Smith et al., 2010), and
for this reason the introduction of bioactive agents, such as
probiotic bacteria, is deemed as a promising approach to
reestablish the gut compositional harmony (Gagliardi et al.,
2018). Historically, the concept of probiotic was firstly put
into a scientific framework by the work of Russian Nobel
laureate Elie Metchnikoff at the Pasteur Institute in Paris
at the beginning of the twentieth century. Based on the
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hypothesis that regular consumption of fermented dairy products
with lactic acid bacteria (LAB) was associated with enhanced
health and longevity in elderly Bulgarian people, Metchnikoff
demonstrated that the consumption of high viable cell numbers
of beneficial lactobacilli via fermented milks prevented the
growth of negative proteolytic bacteria by lowering intestinal pH
and consequently bringing benefits to host health (Metchnikoff,
1907). Thenceforth, the designation probiotic has been related
to beneficial bacteria for the host health, although its definition
has been modified over time (Gomes et al., 2017). Presently,
the most well-accepted scientific definition of probiotic is
“live microorganisms that, when administered in adequate
amounts, confer a health benefit on the host.” Such definition
was proposed by the International Scientific Association for
Probiotics and Prebiotics (Hill et al., 2014) which maintained
an earlier probiotics definition provided by the Food and
Agriculture Organization of the United Nations and World
Health Organization (FAO and WHO, 2001), with only minor
grammatical modifications. Probiotic bacteria, whether ingested
through food or supplements, are considered to be part of
our “transient microbiota,” since their integration into the
resident gut microbiota is temporary. With the recognition
that gut microbiota status has a deep influence on host
health and disease, it is also important to understand that
each individual possesses a resident gut microbiota (Jalanka-
Tuovinen et al., 2011). This stable residency arrangement is
acquired after infancy, where the initial colonization of primarily
facultative anaerobes, such as bifidobacteria, prepare a more
adequate environment for strictly anaerobic bacteria colonization
(Palmer et al., 2007). During our lifetime, certain dietary
choices, antibiotic administration, and the occurrence of disease
defy this somewhat defined structure, but in a healthy adult,
the gut microbiota eventually returns to the primed stable
configuration, largely due to the existing microbial richness
and functional redundancy in gene function (Antonopoulos
et al., 2009; Lozupone et al., 2012). Nevertheless, probiotics
are shown to be able to impact resident communities through
three different possible mechanisms: (1) trophic interactions
with resident members, (2) stimulating/inhibiting community
members’ growth, and (3) inducing a host response, which
indirectly modifies microbiota (Derrien and vanHylckamaVlieg,
2015; Lobionda et al., 2019). In the next section, reasons on how
specific emerging bacterial strains impact or induce alterations in
host health will be presented and discussed.
ANAEROBIC HUMAN-COMMENSALS
SWAY ON HOST HEALTH
As abovementioned, it is now clear that diet is a major
determinant for gut microbiota modulation in adults, increasing
bacterial richness/diversity and functional redundancy, which
in turn contributes to gut community resilience, sustaining a
microbial balance (Selber-Hnativ et al., 2017). The introduction
of bioactive compounds with known biological activity, such
as beneficial microorganisms, through food fortification, or
simple supplementation, for the improvement of gut community
functionality is in effect another tool to further provide health
benefits, apart from those delivered by the ingested nutrients
(Douillard and de Vos, 2019).
Conventional Probiotics: the Current
Health Heroes
Over the past decades, probiotic strains have been isolated
from many sources, including human origin commensal
microorganisms, derived from gut; and non-human origin
resulting from dairy and non-dairy food and beverage
fermentation, fresh fruits and vegetables among others
(Sornplang and Piyadeatsoontorn, 2016). Despite the wide
array of sources, the strains considered probiotic and used
for commercial applications belong mainly to Lactobacillus
and Bifidobacterium genera and are commonly designated
as conventional or classical probiotics (Almeida et al., 2019).
However, it is important to note that other bacterial species
including some members of Bacillus (B. coagulans, B. subtilis),
Streptococcus thermophilus, Escherichia coli Nissle 1917, and the
yeast Saccharomyces cerevisiae variant boulardii are also used
in commercial probiotic products (Gomes et al., 2017). Since
the major aim of this review is to look into commensal obligate
anaerobes only the Bifidobacterium genus will be covered in
this section.
Bifidobacterium
The Bifidobacterium genus is taxonomically included within the
phylum Actinobacteria and contains more than 50 species of
anaerobic, catalase-negative, Gram-positive, non-spore forming
bacteria (Gomes et al., 2017; Hidalgo-Cantabrana et al., 2017).
The optimum temperature for the growth of bifidobacteria is
between 37 and 41◦C with optimum pH ranging between 6.0
and 7.0 (Shah, 2007). In 1899 French pediatrician Tissier first
isolated bifidobacteria from the feces of breast-fed infants and
since then this probiotic group has been incorporated as an active
ingredient into several functional foods, mostly dairy products,
as well as in dietary supplements and pharmaceutical products,
alone, or allied to other microorganisms or microbial substrates
(O’Callaghan and van Sinderen, 2016; Hidalgo-Cantabrana et al.,
2017).
Within the human gastrointestinal tract, the Bifidobacterium
genus features prominently since it is one of the predominant
bacterial populations, being B. pseudocatenulatum,
B. adolescentis, B. longum, B. pseudolongum, B. breve, B. bifidum,
B. animalis, and B. dentium the most frequent bifidobacterial
species found in healthy humans’ stools (Delgado et al.,
2006; Turroni et al., 2009). Furthermore, bifidobacteria play a
pivotal role in maintaining a healthy status through metabolic,
trophic, and protective activities (Delgado et al., 2006; Hidalgo-
Cantabrana et al., 2017). In this alignment, the consumption
of bifidobacteria has been proposed as a way to achieve several
beneficial effects, in both modalities, either prevention or
treatment of intestinal and extra-intestinal disorders. Indeed,
human trials involving supplementation of B. longum (in
capsules) and a yogurt enriched with B. animalis (He et al.,
2008) or a probiotic product containing B. breve and the Yakult
L. casei Shirota (Almeida et al., 2012), demonstrated alleviation
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of symptoms in lactose-intolerant patients. Furthermore, the
commercial probiotic formula containing B. lactis and S.
thermophilus (Corrêa et al., 2005) or the probiotic preparation
VSL#3 (currently known as De Simone formulation) containing
B. breve, B. longum, B. infantis, L. acidophilus, L. plantarum, L.
paracasei, L. delbrueckii subsp. bulgaricus, and S. thermophilus
(Selinger et al., 2013), demonstrated the capacity to either
prevent or reduce the incidence of antibiotic-associated
diarrhea, respectively. In addition, the administration of certain
bifidobacteria strains has been associated with the improvement
of clinical conditions among ulcerative colitis subjects (Miele
et al., 2009; Ishikawa et al., 2011), the decrease of the incidence
and severity of necrotizing enterocolitis among infants (Lin
et al., 2005, 2008) and the reduction of postoperative infectious
complications in colorectal cancer patients (Zhang et al., 2012).
Besides the intestinal disorders’ spectrum, several human
trials have demonstrated that certain bifidobacteria strains are
effective in the prevention and treatment of non-intestinal
immunological diseases including atopic dermatitis (Yeşilova
et al., 2012), eczema (Kim et al., 2010), and seasonal allergic
rhinitis (Singh et al., 2013).
Scientific evidence supporting health-promoting effects
mediated by bifidobacteria is increasing rapidly, yet questions
remain (Tojo et al., 2014; Hidalgo-Cantabrana et al., 2017);
for example, effectiveness of single preparations vs. mixtures
with other strains or with prebiotics, appropriate dose, delivery
system, and duration of intervention. Recommendations of
probiotics, especially in a clinical setting, must relate specific
strains to the claimed benefits based on human studies.
Studied areas in which such good evidence is already available
(i.e., many randomized controlled trials with systematic
reviews/meta-analyses) include gut health (Sánchez et al., 2017);
antibiotic-associated diarrhea (Agamennone et al., 2018); and
irritable bowel syndrome (IBS) (Ford et al., 2018). Other areas
require further studies to support the efficacy and safety of
bifidobacteria products.
The Next Generation of Probiotics:
Understanding their Potential
The emergence of high-throughput sequencing technologies,
with compositional, metagenomic, and metatranscriptomic
analyses is expanding gut microbiome research offering a
profound and extensive assessment of themicrobial communities
present in this complex ecosystem and their interactions
(Papadimitriou et al., 2015). Among those commensal gut
microbial species, some promise to arise as the so called
next-generation probiotics (NGPs), the potential new agents
for more targeted therapies, eliciting positive impact in host
health and disease (O’Toole et al., 2017; Almeida et al., 2019).
In Figure 2, the main species allocated to the NGPs are
listed and the main health promoting effects as well as the
associated limitations are summarized. Hereafter, some of the
most promising bacterial NGP candidates cited in literature are
reviewed and discussed with special focus on their host-health
promoting effects.
Akkermansia
Considering that cardiometabolic traits such as type 2 diabetes
and obesity are a severe epidemic health issue well-documented
in developed countries and increasing in prevalence in
developing countries (GBD 2015 Obesity Collaborators et al.,
2017), pinpointing pivot players in this type of morbidity is of
utmost importance. One of the key elements demonstrating to
be inversely associated with such pathologies is Akkermansia
muciniphila (phylum Verrucomicrobia), an oval-shaped, non-
motile, strict anaerobe, Gram-negative bacterium (Derrien et al.,
2004), which represents ∼1–3% of the total fecal material
(Derrien et al., 2008; Cani and Everard, 2014; Schneeberger
et al., 2015). Akkermansia muciniphila is an abundant colonizer
of the intestinal mucus layer with a proficiency to degrade
its main component—mucin, an important mediator of the
gut barrier function (Derrien et al., 2017). This specialization
not only initiates a trophic mucin cross-feeding cascade in
which A. muciniphila acts as a keystone species by sustaining
the overall equilibrium of the gut bionetwork (Belzer et al.,
2017; Chia et al., 2018), but also reduces gut permeability
allowing the fortification of the enterocyte monolayer integrity
which is further reinforced by the production of short-chain
fatty acids (SCFAs) and extracellular vesicles (Reunanen et al.,
2015; Cani and de Vos, 2017). Regarding the specificities of
cardiometabolic features, there is already a substantial amount of
data correlating A. muciniphila with the improvement of blood
glucose homeostasis, host lipidmetabolism, body fat distribution,
and low-grade inflammation markers, amongst others (Derrien
et al., 2011; Lukovac et al., 2014; Schneeberger et al., 2015;
Dao et al., 2016a; Greer et al., 2016; Li et al., 2016; Wu
et al., 2017; Chelakkot et al., 2018). This positive effect on gut
barrier function and energy homeostasis has been attributed to
various putative targets, such as the endocannabinoid system
and the antimicrobial peptide RegIIIgamma (Everard et al.,
2011, 2013). Curiously, it has been hypothesized that the
metabolic parameters ameliorations could also be impacted
by particular cell-wall components, more specifically by the
protein Amuc_1100 which is also implicated in the formation
of pili and doesn’t seem to be affected by heat treatments.
Plovier and colleagues found that this protein has an important
immunomodulatory action in both in vitro and in vivo
models and, may be partly responsible for reduction in fat
mass development and dyslipidemia, while improving insulin
tolerance (Plovier et al., 2016; Ottman et al., 2017). In fact,
the same research group led by Dr. Cani went further by
recently demonstrating in a randomized, double-blind, placebo-
controlled pilot study, that the daily oral supplementation of
pasteurized A. muciniphila in overweight individuals aided the
reduction of metabolic parameters such as insulin resistance,
cholesterol, and fat mass deposits, also recognized to be
cardiovascular risk factors, whilst decreasing blood markers for
inflammation and liver disfunction (Depommier et al., 2019).
This sort of proof-of-concept study is a tremendous landmark
by demonstrating the human practical probiotic potential of
A. muciniphila. Finally, A. muciniphila also seems to play an
important role in the response of cancer immunotherapy. Routy
et al. reported that patients with a positive response to the
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FIGURE 2 | Next generation probiotics and its Duality: health promoting-effects vs. limitations.
immune checkpoint inhibitor PD-1 antibody exhibit higher
intestinal abundance of this NGP when compared to non-
responders. In fact, oral supplementation of A. muciniphila
to mice that received human non-responder fecal microbiota
transplantation (FMT) restored PD-1 treatment efficacy (Routy
et al., 2018).
Notwithstanding its multiple functionalities, application of
this NGP should go with caution, as the presence of pre-
existing conditions such as infection by pathogenic Enterococcus
and Shigella may lead to a compromised gut barrier integrity
and function, causing an increased uptake of proteins in
the gastrointestinal tract thereby exacerbating allergenic and
inflammatory conditions (Sonoyama et al., 2010; Zheng et al.,
2016). Furthermore, in a previous study A. muciniphila was
identified in numbers about 4-fold higher in colorectal cancer
patients when compared to healthy subjects (Weir et al.,
2013). It is important to note, however, that A. muciphila
increase is correlated with fasting (Remely et al., 2015) and
cancer patients normally have a reduction in food intake.
Moreover, an enhanced mucus production is related with this
form of cancer pathophysiology, which could concurrently
stimulate A. muciniphila abundance (Gómez-Gallego et al.,
2016). Additionally, data on the evaluation of specific features
viewed as important for the screening of A. muciniphila’s
probiotic potential were recently investigated. Cozzolino et al.
(2020) assessed probiotic properties such as co-aggregation,
biofilm formation, and antimicrobial activity and found that
A. muciniphila DSM 22959 revealed good co-aggregation
capacity to pathogenic strains such as Enterococcus faecalis,
Staphylococcus aureus, and Proteus mirabilis, and displayed
resistance to chloramphenicol, clindamycin, streptomycin, and
erythromycin, despite low aptitude for biofilm formation.
Indeed, the need for a more comprehensive physico-chemical
characterization of this strain is still necessary in order for it to be
properly tested safe and introduced in an industrial framework in
the near future. Nevertheless, since reduction in A. muciniphila
numbers might lead to the onset or aggravation of metabolic
disorders, this possible biomarker of a healthy host metabolic
profile could present a powerful weapon in the fight against
cardiometabolic diseases (Schneeberger et al., 2015; Dao et al.,
2016a; Cani and de Vos, 2017).
Faecalibacterium
Several human commensal gut bacteria have been shown
to produce SCFAs, metabolites with associated biochemical
impact on the host, but growing evidence pinpoints specifically
the butyrate-producer Faecalibacterium prausnitzii as a strong
candidate for therapeutic approaches regarding inflammatory
diseases (Miquel et al., 2013; Heinken et al., 2014; Foditsch
et al., 2015; Munukka et al., 2017). Faecalibacterium prausnitzii
is described as a Gram-positive, extreme oxygen-sensitive (EOS),
SCFAs producer (Duncan et al., 2002; Foditsch et al., 2014)
and, the only identified species of the Faecalibacterium genus
which is part of the family Ruminococcaceae family also
known as Clostridium cluster IV (phylum Firmicutes), a group
of bacteria considered to be major players in the human
microbiota (Lopetuso et al., 2013). The relative abundance
of this commensal renders its importance, since it represents
around 5–20% of the total bacterial gut population in stools
of healthy subjects (Tap et al., 2009; Miquel et al., 2013).
Concurrently, the substantial growing evidence suggests that
the low proportion of F. prausnitzii characterizes a microbial
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dysbiosis linked to an inflammatory phenotype, such as IBS,
inflammatory bowel disease (IBD), specifically Crohn’s disease
and ulcerative colitis (Sokol et al., 2008; Candela et al., 2012;
Miquel et al., 2013, 2016). Provided that it is maintained within a
non-dysbiotic state, F. prausnitzii’s protective effect is associated
with a specific metabolite profile, in particular butyrate, which
serves as a valuable energy source for colonocytes, acts as an
anti-inflammation promotor and shows capacity to improve
metabolic syndrome (Ohira et al., 2017). Indeed, it has been
demonstrated that butyrate producers are usually often reduced
in a dysbiotic gut microbiota community when compared to
healthy controls (Rivera-Chávez et al., 2016). In the same way,
F. prausnitzii is also able to mechanistically achieve additional
anti-inflammatory effects through the secretion ofmicrobial anti-
inflammatory molecules (MAM) and extracellular polymeric
matrix (EPM) (Rossi et al., 2015; Quévrain et al., 2016; Breyner
et al., 2017). This specific taxon was also found to be involved
with the stimulation of mucin and tight-junction proteins
synthesis, which are pivotal components of a primed mucosal
barrier integrity (Lopez-Siles et al., 2012; Carlsson et al., 2013;
Rossi et al., 2015). Another key point is the interesting metabolic
network in themucosal layer involving F. prausnitzii and primary
degraders such as A. muciniphila, which produce acetate, the
primary precursor for F. prausnitzii butyrate production, proving
that key commensal strains require metabolic cross-feeding
partnerships for regulation of health status of the host (Belzer
et al., 2017).
In the light of the immense potential of F. prausnitzii as
an NGP, according to our knowledge, there are no published
reports on safety risks for the usage and application of this EOS
commensal as a therapeutic tool which emphasizes the demand
for further research.
Eubacterium
Given its capacity to be one of the few strains belonging to
Clostridium cluster XIV (phylum Firmicutes) with the special
ability to convert the metabolic intermediate lactate into butyrate
(Duncan et al., 2004), Eubacterium hallii is slowly emerging as a
NGP candidate (Udayappan et al., 2016). Eubacterium hallii, is a
Gram-positive, EOS bacterium that colonizes the gut after birth
reaching adult levels around 10 years of age (Schwab et al., 2017).
Although, it has been recently reclassified as Anaerobutyricum
hallii (Shetty et al., 2018), this bacterium is still being referred to
as E. hallii in the subsequent publications (Chang et al., 2020).
This human colonic “lactate-utilizer” is not able to metabolize
complex oligo- and polysaccharides and thus, is at some extent
dependent on cross-feeding relationships in order to obtain the
appropriate substrate supply for SCFAs production (Scott et al.,
2014). For instance, in co-culture experiments it has been shown
that the production of lactate by saccharolytic bacteria, such as
Bifidobacterium spp., and 1,2-propanediol via fucose degradation
by A. muciniphila, grants E. hallii the necessary precursors for
butyrate and propionate production, respectively (Engels et al.,
2016; Belzer et al., 2017; Schwab et al., 2017). The specialization
on lactate utilization is one of the key traits of this colonic
anaerobe, which attributes it a relevant role in the balance
of intestinal metabolism, considering that lactate accumulation
leads to the onset of various disorders, in particular short bowel
syndrome (Belenguer et al., 2007; Kowlgi and Chhabra, 2015).
Equally important, is the identified E. hallii ability to convert,
via glycerol metabolism, PhIP—a carcinogenic heterocyclic
amine formed in meats during cooking—to the glycerol
conjugate PhIP-M1, which holds a much lower mutagenic
potential, yielding a possible detoxification activity strategy of
intestinal microbiota (Fekry et al., 2016).
Ultimately, E. hallii is presented as an exciting prospect for
gut microbiota modulation due to the ability of ameliorating
intestinal disorders and host health profile, however more
extensive research is necessary to fully understand the overall
impact this anaerobic colonic commensal exerts on host health.
Prevotella
The Prevotella genus, which belongs to the Bacteroidetes phylum,
encompasses over 30 different strains, mostly found in the oral
cavity and in the gut (Ley, 2016). One of the most abundant
species of this genus in the gut is Prevotella copri, a non-
spore forming, obligate anaerobic Gram-negative rod that can
be present in human feces (Hayashi et al., 2007). Prevotella copri
has been appointed as a beneficial bacterium associated with
a plant-rich diet. In fact, Kovatcheva-Datchary and coworkers
demonstrated that subjects with improved glucose metabolism
after barley kernel supplementation have increased Prevotella in
their gut microbiota. Moreover, these researchers showed that
P. copri is a succinate producer, since mono-colonization of
germ-free mice with P. copri significantly increased succinate
levels in the cecum, with no increase in any other carboxylic
acids, whilst improving glucose homeostasis with concomitant
enhancement of liver glycogen content (Kovatcheva-Datchary
et al., 2015). Succinate, or succinic acid is a carboxylic acid that
acts as an intermediate in propionate synthesis and activates
intestinal gluconeogenesis (de Vadder et al., 2016). Identically
to A. muciniphila, P. copri is one of the few NGPs that has
been researched via functional proof-of-concept trials. Indeed,
de Vadder et al. (2016) showed that the improvement in
glucose metabolism and insulin sensitivity provided by P. copri
was related with the succinate production that resulted from
the bacterial fermentation of dietary fibers. In spite of these
promising findings, as in the case of A. muciniphila, a specific
bacterium can present contrasting results on host health, which
is ultimately affected by any of the factors, such as diet, prevailing
in the complex human gut ecosystem. In fact, Pedersen and
colleagues discovered that P. copri is among the bacterial species
that correlate with a branched-chain amino acids biosynthesis
enriched microbiome. Moreover, using a mice model they
demonstrated that P. copri administration can worsen insulin
resistance and exacerbate glucose intolerance, when coupled with
a high fat diet (Pedersen et al., 2016). Furthermore, P. copri has
also been involved in pathogenesis of rheumatoid arthritis (Scher
et al., 2013) and it has been linked to mucosal inflammation in
HIV subjects (Dillon et al., 2016). Due to the abovementioned
paradoxical findings, P. copris host modulation is likely to be
dependent on dietary intake which demands further studies in
order to carefully assess whether P. copri plays a beneficial role or
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could incur deleterious effects in human health (Ley, 2016; Cani,
2018).
Bacteroides
Considering that the genus Bacteroideswas found to be extremely
heterogeneous, phenotypically and phylogenetically, in 1989 this
group was restricted to a more coherent taxonomic set of
species (Shah and Collins, 1989). Within this group, B. fragilis,
B. uniforms, and B. xylanisolvens, which are anaerobic, bile-
resistant, non-spore-forming, Gram-negative rods frequently
found in human gut, are being considered as potential candidates
for a new generation of probiotics (Wexler, 2007; Neef and Sanz,
2013; Chang et al., 2019; Douillard and de Vos, 2019).
During several years, B. fragilis was considered to be an
anaerobic pathogen responsible for a range of diseases involving
a permeable intestinal barrier (Sun et al., 2019). However,
recent studies demonstrated that non-toxigenic B. fragilis strains
exert immunomodulatory effects on host diseases namely the
inhibition of inflammation in different organs (Ochoa-Repáraz
et al., 2010; Chang et al., 2017; Johnson et al., 2018), prevention
of infection by pathogenic agents (Sommese et al., 2012; Li et al.,
2017), and support of cancer therapy (Sittipo et al., 2018), mainly
mediated by its polysaccharide A and outer membrane vesicles
(Sun et al., 2019).
Regarding B. uniformis, it is considered a potential probiotic
that is commonly found in breast-fed infants (Sánchez et al.,
2011). Interestingly, oral administration of B. uniformis CECT
7771 strain in high-fat- diet induced obesity mice reduced body
weight gain, dietary fat absorption and liver steatosis. Also, this
strain decreased serum levels of cholesterol, triglyceride, glucose,
insulin, and leptin and simultaneously enhanced immune
defense mechanisms (Cano et al., 2012). Thus, the administration
of B. uniformis CECT 7771 may improve metabolic and immune
dysfunction related to intestinal dysbiosis in obesity settings.
Moreover, acute oral consumption of B. uniformis CECT 7771
does not entail safety concerns in mice, but further studies should
be conducted in humans (Fernández-Murga and Sanz, 2016).
In comparison, B. xylanisolvens exhibits immune-modulatory
properties and it is able to ferment xylan and other sugars with
SCFAs production (such as acetate, propionate, and succinate)
which is linked to health-promoting effects (Chassard et al.,
2008; Ulsemer et al., 2012b). Moreover, the strain B. xylanisolvens
DSM 23964 has no virulence potential and is able to survive
in harsh gastrointestinal conditions, an important prerequisite
for a bacterial strain to be categorized as probiotic (Ulsemer
et al., 2012b). Pasteurized B. xylanisolvens DSM 23964 strain
is safe and well-tolerated by healthy humans (Ulsemer et al.,
2012a). Moreover, this strain was recently authorized as a starter
in the fermentation of pasteurized milk products under Novel
Food Regulation No. 258/97 by the European Commission
(EFSA Panel on Dietetic Products, Nutrition and Allergies,
2015). Notably, this approval only allows heat-inactivated
B. xylanisolvens in fermented milk products which contradicts
the very principle of probiotics which is the administration of live
cultures to the consumer. Therefore, further studies with alive
B. xylanisolvens are required in order to increase the likelihoods
of acceptance within the probiotic market (Brodmann et al.,
2017).
Christensenella
Apart from diet, genetic predisposition is another factor
influencing host phenotype. Indeed, the bidirectional interaction
between host genes and gut microbiome is of interest for
the development of approaches targeting metabolic disorders.
With the goal of examining the impact of host genetics on
microbial taxa, Goodrich et al. (2014) demonstrated that the
Christensenellaceae family is the most highly heritable taxon
which forms the hub in a co-occurrence network with other
heritable taxa and with methanogenic Archaea and it is enriched
in individuals with low body mass. Through experiments
using fecal transplants into germ-free mice, these authors also
verified that obesity-associated microbiome is ameliorated by
Christensenella minuta which reduces the weight gain and
alters the microbiome pattern of recipient mice. As the first
member of the family Christensenellaceae (phylum Firmicutes),
C. minuta is a strictly anaerobic, non-spore-forming, Gram-
negative rod that can be found in human feces (Morotomi et al.,
2012) and, is another potential candidate for future probiotic
formulations. Alongside the potential use of C. minutawithin the
framework of obesity, the genus Christensenella was positively
related with type 1 diabetes (de Groot et al., 2017) and recently
C. minuta was isolated in a mixed infection together with
Desulfovibrio desulfuricans from the blood of a patient with acute
appendicitis (Alonso et al., 2017). Similarly, to other Gram-
negative bacteria, C. minuta possesses lipopolysaccharides (LPS),
an outer membrane component that is considered a virulence
factor. Nonetheless, it was demonstrated that LPS of C. minuta
is genetically and structurally different with a weaker agonist
activity for RAW 264.7 macrophages when compared with LPS
of E. coli (Yang et al., 2018). Although these studies suggest
that C. minuta might be directly connected with protection
against obesity, further studies will be needed to fill in the gaps
concerning the whole clinical spectrum of this bacterium, in
regard to its health promoting effects as well as its pathogenic
profile, before proceeding to human trials with this NGP
candidate (Alonso et al., 2017; Douillard and de Vos, 2019).
Butyricicoccus Pullicaecorum
The increasing causal evidences linking the depletion of butyrate-
producing bacteria in the intestinal ecosystem to the onset
of inflammatory conditions has been attracting increasing
attention due to its clinical applications. In this context, the
butyrate producer Butyricicoccus pullicaecorum is considered
to play a major part in gut health due to its beneficial
effects on inflammatory bowel disorders (Eeckhaut et al., 2013).
Firstly, isolated from the caecal content of a broiler chicken,
B. pullicaecorum is a Gram-positive, anaerobic bacterium
belonging to the phylum Firmicutes (Eeckhaut et al., 2008).
Following the observation of the reduced abundance of the genus
Butyricicoccus in fecal samples of IBD patients, B. pullicaecorum
was selected for further analysis. Eeckhaut and coworkers
reported that oral administration of this bacterium resulted in a
decrease of lesion sizes and inflammation in a rat colitis model.
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org 7 June 2020 | Volume 8 | Article 550
Andrade et al. Commensal Obligate Anaerobic Bacteria and Health
In parallel, in vitro assays demonstrated that the supernatant of
B. pullicaecorum cultures prevented cytokine-induced epithelial
integrity losses (Eeckhaut et al., 2013). Similarly, Bajer and
colleagues verified that ulcerative colitis was related to a
reduction in B. pullicaecorum abundance (Bajer et al., 2017).
Is also of importance to note that whole genome sequencing
revealed that B. pullicaecorum 25-3T strain is non-pathogenic
with restricted antimicrobial resistance potential (Steppe et al.,
2014). This safety profile was further reinforced when this strain
was shown to be safe and well-tolerated by rats (Steppe et al.,
2014) and humans (Boesmans et al., 2018). Also, the favorable
intrinsic tolerance of B. pullicaecorum 25-3T strain to stomach
and small intestinal conditions is an additional feature that
renders this microorganism a very interesting option for future
probiotic applications (Geirnaert et al., 2014).
Parabacteroides Goldsteinii
Years after the Bacteroides genus thorough revision, Sakamoto
and Benno (2006) reclassified three Bacteroides strains into
the novel genus Parabacteroides spp., due to phylogenetically
divergences. Among the different strains, Parabacteroides
goldsteinii exhibits potential to stand for a NGP position
(Chang et al., 2019). Belonging to the phylum Bacteroidetes,
P. goldsteinii is a Gram-negative, obligate anaerobic, non-spore
forming rod with a high potential as a novel probiotic in obesity
and related metabolic disorders (Sakamoto and Benno, 2006;
Wu et al., 2019). Recently, the oral administration of live P.
goldsteinii to obese mice was able to prevent body weight gain,
enhance intestinal integrity and reduce inflammation and insulin
resistance (Wu et al., 2019). However, the beneficial role of
this bacterial species should be thoroughly analyzed since P.
goldsteinii was previously linked to clinical infections of human
intestinal origin (Song et al., 2005; Awadel-Kariem et al., 2010).
Anaerobic Probiotic Technologies: the
Obstacles
Notwithstanding the emerging proof-of-concept data validating
the favorable functional health effects on host fitness by
probiotic anaerobes their introduction in pharmaceutical and
nutraceutical products unravels several challenges for both
industry and researchers (Douillard and de Vos, 2019). One of
the issues facing anaerobic development is related to adequate
presumptions of safety (O’Toole et al., 2017). According to
FAO criteria guidelines, every strain must be correctly identified
and followed by several in vitro assays in order to explore
its functional properties. After taxonomic identification and
functional properties investigation, potential probiotics must be
characterized in terms of safety and technological usefulness
(FAO and WHO, 2001). In this context, Bifidobacterium
and Lactobacillus species are classified either as “Generally
Regarded as Safe” (GRAS) by the United States Food and
Drug Administration (FDA) or, as Qualified Presumption of
Safety (QPS) by the European Food Safety Authority (EFSA)
(Martín and Langella, 2019). On the other hand, interventional
studies on anaerobic NGPs commensal supplementation in
humans are still scarce, and their tolerability, safety, and
efficacy data are limited; since probiotic use should be
evidence-based, additional functional proof-of-concept studies
are imperative for these microorganisms in order to explore the
specificities of the molecular targets and metabolites involved
in the causal relationship between a particular microorganism
and health/disease condition, and thus develop adequate
therapies. Equally important, such demonstrations will also
shape the design of technological/industrial approaches in
order to properly commercialize these probiotic candidates.
Considering that maintaining cell viability and metabolic
activity is of essence for potential probiotic functional food
incorporation and disease therapy inclusion, in the next
section we will review the technological barriers and challenges
that researchers have been attempting to surpass for their
effective delivery, and which tactics are being adopted to
overcome them.
PRODUCTION, STORAGE AND DELIVERY
OF ANAEROBIC COMMENSALS
Following a proper strain characterization, safety assessment, and
documented evidence-based analyses from human studies, it is
important to establish appropriate production technologies and
suitable delivery vehicles/formulations to guarantee the supply
of sufficient viable cell numbers until time of consumption
(Dodoo et al., 2017; Gomes et al., 2017). Several constraints
are known to challenge the viability and efficacy of these
bacteria, which are generally associated to industrial processes
and storage conditions. Indeed, the typical stressors go beyond
the clear oxygen-sensitive nature of these commensals, in that
low levels of pH, heat treatment, water activity (Aw), the
physicochemical properties of matrices, dehydration processes,
and other factors can be responsible for possible viability
reductions (Terpou et al., 2019). Moreover, when the stress
factors faced during the biomanufacturing process and storage
duration are bypassed, formulations don’t guarantee the cultures
protection from the harsh environment conditions of the
gastrointestinal tract (GIT). Once ingestion occurs bacteria
will face a hostile physicochemical and biological environment
composed of low pH levels, digestive enzymes, and bile salts
which could affect their cell structure (Barer, 2015). Considering
that, to provide a clinically positive impact on the host, probiotics
should reach colonic environment in a range of 107-109 CFU per
product dose (depending of vehicle—food, capsule, or sachet),
the so-called “minimal therapeutic” level (Hill et al., 2014;
Hungin et al., 2018), then researchers are required to devise
feasible technological approaches that assure these susceptible
anaerobic commensal strains can exert efficaciously their
beneficial influence on the consumer. Such endeavors are already
taking place, namely through the adaptation of standardized
experimental protocols, inclusion in formulations/food matrices
(incorporation of protective compounds), cell immobilization
systems and application of sub-lethal stress treatments, albeit
their efficacy will depend on the individual capacity each bacteria
holds to adapt and resist to the various techniques (Carding
et al., 2015). As such, in the following section some of the
current technological strategies implemented will be discussed,
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FIGURE 3 | Schematic representation of the industrial production of bifidobacterial biomass (adapted from Gomes et al., 2017).
with focus on their ability to protect the classical probiotics
as well as the new potential anaerobic NGPs when exposed to
detrimental conditions during production process, storage and
GIT passage.
Bifidobacteria
Bifidobacteria have been used for a long time now, especially
in the development of foods and food supplements. Due to
this usage, large-scale biomass production is already established.
However, there is limited information in the literature about
industrial production of bifidobacteria biomass which, according
to El Enshasy et al. (2016), may be due to difficulties in cultivating
them (owing to their anaerobic growth characteristics) and to
their high industrial potential leading to research protection
under intellectual property rights or as trade secrets.
The manufacturing processes of bifidobacteria follow the
same general steps of the production systems of other industrial
microorganisms (i.e., lactic acid bacteria or yeasts) (Gomes et al.,
2017) as systematized in Figure 3. A stock-culture (checked
for strain purity and absence of contaminants) is used in a
specific number of sequential seed fermentations to achieve
the desired inoculum volume and transferred to the main
fermenter for growth. The medium used in the propagation and
main fermentation is composed of carbon (carbohydrates) and
nitrogen sources, minerals, and growth factors and is heat-treated
before being used. Fermentation parameters such as growth
temperature, pH, and the base used to control it, have an impact
on the final product performance and characteristics and are
dependent on the specific strain being cultivated (Ouwehand
et al., 2018) and therefore, should be carefully controlled. After
the fermentation is completed, the cells are concentrated by
separating them from the cultivation broth, usually, through
centrifugation. The concentrated biomass is normally stabilized
by dehydration processes with freeze-drying (lyophilization) and
spray-drying being the most widely used techniques (Broeckx
et al., 2016). Each step should be optimized for the specific strain
being produced as it can impact the robustness of the product
and its ability to recover after rehydration (Ouwehand et al.,
2018).
Fermentation Technologies
In Table 1 one may find a summary of the fermentation
systems reported in the literature for bifidobacterial cultivation.
Batch cultivation with suspended cells is the most used process
for probiotic biomass production at industry level owing to
its simplicity of operation (Champagne and Møllgaard, 2008;
Santos et al., 2015; El Enshasy et al., 2016). In this process,
the culture inoculum is added to the fermenter containing
the culture medium and fermentation is conducted until the
desired cell concentration is achieved. Once the fermentation
is finished, the cells are harvested, and the process is repeated.
The main disadvantage of this process is low biomass yields
due to the accumulation of metabolic end-products such as
lactic and acetic acids, and/or substrate depletion (Doleyres and
Lacroix, 2005). To improve biomass concentration, fed-batch
fermentation has also been applied to bifidobacteria production
(El Enshasy et al., 2016). This fermentation technique allows
the addition of a limiting substrate during the fermentation,
which can help increase the bacterial concentration. Fed-batch
can also be applied to adapt bacteria to a specific carbon source
or to induce a stress response to protect them from subsequent
processing steps.
The use of continuous cultures has also been investigated
to produce bifidobacteria (Doleyres and Lacroix, 2005). After
optimization, this technology can lead to both high cell yield
and volumetric productivity and to contribute to decrease in
the demand for downstream processing. However, the use
of continuous fermentations at industrial scale may be more
difficult as they are highly susceptible to contamination and to
cell instability. Nevertheless, this technology has shown some
potential to obtain cells with different physiologies and to
apply stresses under well-controlled conditions (see also section
Improving the Stress Tolerance of Bifidobacteria) (Lacroix
and Yildirim, 2007). For example, a two-stage continuous
fermentation has been used to screen sublethal stress conditions
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TABLE 1 | Selected bifidobacteria fermentation systems reported in the literature.
Strain Fermentation system Culture medium Biomass References
B. longum ATCC 15707 Batch culture
Continuous culture/IC
MRS—WP 1.7 × 1011 cfu.mL−1
4.9 × 109 cfu.mL−1
Doleyres et al., 2002
B. infantis ATCC 17930 Batch culture TPYG 2.1 g.L−1 González et al., 2004
B. longum CCRC 14634 Batch culture
Fed-batch culture
Complex medium 1.3 × 109 cfu.mL−1
5.2 × 109 cfu.mL−1
Her et al., 2004
B. bifidum BGN4 Batch culture
Continuous culture/MR
Complex medium 3.0 × 109 cfu.mL−1
2.2 × 1010 cfu.mL−1
Kwon et al., 2006
B. pseudocatenulatum G4 Batch culture Milk-based medium 1.687 × 109 cfu.mL−1 Stephenie et al., 2007
B. longum NCC2705 Continuous culture/IC MRS 2.0 × 109 cfu.mL−1 Mozzetti et al., 2010
B. longum ATCC 15707 Batch culture
Continuous culture/MR
Complex medium 6.0 × 109 cfu.mL−1
1.2 × 1011 cfu.mL−1
Jung et al., 2011
B. longum NCC2705 Continuous culture/IC MRSC 8.6 × 109 cfu.mL−1 Reimann et al., 2011
B. bifidum THT 0101 Batch cultures MRSC 1.2 × 109 cfu.mL−1 Nguyen et al., 2015
B. crudilactis FR62/b/3 Batch culture MRS 8.3 × 109 cfu.mL−1 Tanimomo et al., 2016
IC, culture with cells immobilized in gel beads; MR, membrane reactor; MRSC, de Man, Rogosa and Sharp medium supplemented with L-cysteine; WP, Whey permeate; TPGY, trypticase
peptone yeast-extract glucose medium.
for improvement of Bifidobacterium longum (Mozzetti et al.,
2013). A first reactor was operated under normal conditions,
whereas a second reactor, placed in series, was operated under
stress conditions. A significant improvement in cell resistance to
heat lethal stress (56◦C, 5min) was achieved for cells pretreated
at 47◦C in this manner. In another approach, Mozzetti et al.
(2013) used continuous cultures combined with immobilized cell
technology to select for hydrogen peroxide adapted B. longum
cells (Mozzetti et al., 2010). A stable strain with higher tolerance
to oxygen than the wild type cells was isolated in thismanner. Cell
immobilization consists of physical confinement or localization
of microorganisms in a fermentation system to attain high cell
concentrations (Doleyres and Lacroix, 2005). Besides high cell
densities, several other advantages over free-cell fermentations
have also been reported including: the possibility of reusing the
cells, improved resistance to contamination and bacteriophage
attack, enhanced plasmid stability, prevention from washing-
out during continuous cultures, and the physical and chemical
protection of cells (Lacroix and Yildirim, 2007). There are several
methods for immobilizing microorganisms but for bifidobacteria
two of them are the most used, namely immobilization in
polysaccharide gel beads and membrane bioreactors (Doleyres
and Lacroix, 2005). Continuous cultures with B. longum
immobilized in gellan gum gel beads produced high cell
concentrations and 4-fold increased volumetric productivity at
a dilution rate of 0.5 h−1 when compared with free-cell batch
cultures (Doleyres et al., 2002). Kwon et al. (2006) reported
seven times higher concentrations of B. bifidum, compared to
batch cultures, when using a submerged membrane bioreactor.
Similarly, Jung et al. (2011) also reported higher cell yields
using a membrane reactor as opposed to free cell fermentation
of B. longum. In a membrane system with a constant feeding
of fresh medium, the bacteria are kept in the bioreactor by
an ultrafiltration or microfiltration membrane. Any growth
inhibitory metabolites are removed from the system in this way,
allowing for more bacterial growth. The concentrated biomass
can be harvested with no or minimal additional downstream
treatment for cell concentration before stabilization.
Factors Affecting Stability and Resistance of
Bifidobacteria
The manufacturing process should result in a highly
concentrated biomass without detrimental effects on the
cells. The microorganisms must be metabolically stable during
processing and active in the product and remain viable at
sufficiently high levels during the gastrointestinal tract transit in
order to exert the beneficial effects in the host. However, during
the manufacture and storage, bifidobacteria may be submitted
to several stresses such as osmotic, heat, and cold or exposure to
oxygen, which may have a detrimental impact on cell viability
and hence on its functionality (Ruiz et al., 2011). Furthermore,
after oral ingestion, bifidobacteria have to cope with low pH in
the stomach and with high bile salt concentrations and digestive
enzymes in the small intestine.
Oxygen
Bifidobacteria are considered anaerobes but their oxygen
sensitivities are reported to vary among the species. Among the
most studied species of bifidobacteria, B. animalis subsp. lactis is
considered oxygen tolerant, B. bifidum, B. breve, and B. longum
are oxygen-sensitive (grow in the presence of 5% O2 in liquid
culture) while B. longum subsp. infantis and B. adolescentis are
considered oxygen-hypersensitive (growth inhibited in 5% O2
conditions) (Kawasaki et al., 2018). Oxygen stress can affect
bifidobacteria during their production, downstream processes,
and storage as strict anaerobic conditions are not easily
maintained in all these steps. Oxidative damage is mainly due
to the production of reactive oxygen species (the superoxide
anion radical O−2 , the hydroxyl radical OH
•, and hydrogen
peroxide H2O2) which can critically damage proteins, lipids,
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and DNA. Ahn et al. (2001) reported a longer lag phase
and morphological changes associated with changes in protein
and fatty acid profiles of B. longum growing in the presence
of oxygen. Ninomiya et al. (2009) reported that growth and
exopolysaccharide (EPS) production of a B. longum JBL05 strain
decreased with dissolved oxygen concentrations above 0.05 ppm.
Decreased EPS production during culture may have an impact
on the ability to adhere to the intestinal epithelium. In contrast,
Qian et al. (2011) reported that different bifidobacteria strains
grown in culture media without the reducing agent, cysteine
(thus under oxidative stress), showed greater intracellular granule
production, in response to oxidative stress, when compared
with those grown in reducing media (with cysteine added).
Additionally, those grown under oxidative stress showed higher
EPS production, acid tolerance, and cell surface hydrophobicity,
which has been positively correlated with adhesion ability to
host cells.
Heat and cold stress
Bifidobacteria may be exposed to heat and/or cold during the
biomass stabilization and storage phases of its manufacture (see
Figure 1). When spray-drying is used (see also section Drying
Processes), bifidobacteria can be exposed to temperatures as high
as 200◦C (Broeckx et al., 2016) and although the cells are not
constantly subjected to such high temperatures, the integrity of
viable bifidobacteria cells can be severely compromised. High
temperatures can cause denaturation of proteins and destabilize
membranes, conceivably leading to cell death. Simpson et al.
(2005) screened different bifidobacterial strains for heat and
oxygen tolerance and these were subsequently spray dried,
and their viability assessed during storage. It was found that
survivability was best for bacteria with high oxygen and heat
tolerance. Bifidobacterium animalis subsp. lactis showed more
than 70% survival after spray drying in reconstituted skim milk
(20%, w/v) at an outlet temperature of 85–90 ◦C. Furthermore,
Bifidobacterium strains that had better heat and oxygen tolerance
also exhibited better stability during storage.
Freeze-drying is a milder process than spray-drying resulting
in higher cell viability. However, the low temperature still
compromises cellular integrity with the main consequences
being reduction in membrane fluidity, protein folding, and
disturbance of enzyme activity (Mills et al., 2011). To increase cell
viability during freeze drying and storage some cell-protecting
agents such as skimmed milk powder, milk whey, butter milk,
trehalose, sucrose, or lactose are usually added (see also section
Drying Processes).
Osmotic stress
During dehydration, the osmolality of the milieu increases,
leading to excessive passage of water from the cell to
the extracellular environment that compromises essential cell
functions (Poolman, 2002).
Acid
After ingestion, bifidobacterial cells are challenged with the
severe acidic conditions in the stomach (pH > 2). Exposure
to acid leads to a proton accumulation inside the cell that
may negatively affect the proton motive force (PMF) across
the membrane. Besides cell membrane structural damage
caused by changes in PMF, acid stress also causes damage
to nucleic acids and proteins (Anandharaj et al., 2017).
Bifidobacteria are generally considered to have low tolerance
to exposure to acidic conditions. Moderate tolerance to low
pH after 60min of exposure was reported for strains of
B. longum, B. breve, or B. dentium strains by Andriantsoanirina
et al. (2013). Bifidobacterium adolescentis, B. bifidum, and
B. pseudocatenulatum strains showed acid tolerance for only a
short time.
Bile
Bile acids and salts are the main components of bile and are
the responsible agents for its antimicrobial and detergent-like
properties. Bile acids are weak organic acids that can passively
enter the bifidobacteria cytoplasm (Kurdi et al., 2006). This
intracellular accumulation of deconjugated bile acids have a
profound impact on the cell metabolic processes, causes leakage
of ions and other cellular components, and ultimately, may lead
to cell death (Ruiz et al., 2011). The resistance to bile is very
dependent on the species within the Bifidobacterium genus. It
has been stated that almost all bifidobacteria possess metabolic
capacity to cope with bile acids namely, by deconjugating them
via mediation of a bile salt hydrolase (El Enshasy et al., 2016).
Improving the Stress Tolerance of Bifidobacteria
Different Bifidobacterium strains may present big differences
in their tolerance to technological and gastrointestinal stresses
as seen above. Improving stress tolerance of bifidobacteria,
and therefore ensuring their high survival, is important for
both economic reasons and health effects. In this regard, stress
adaptation by using exposure to sub-lethal conditions has been
an important area of research (Ruiz et al., 2011). Like other
microorganisms, when bifidobacteria are exposed to sub-lethal
stresses, the tolerance to subsequent stresses is improved. This
exposure leads to an adaptation to adverse environments, which
is normally associated with the induction of many genes, the
synthesis of shock-proteins and the development of cross-
resistance to other types of stress (Santos et al., 2015). Collado
and Sanz (2007) reported that 15min heat shock at 47◦C
enhanced B. longum’s thermotolerance 24–128 folds. The same
authors also reported that prolonged incubation at pH 2.0
generates acid resistant strains of B. longum and B. catenulatum.
Moreover, the adapted strains showed higher resistance to bile
salts (1–3%), NaCl (6–10%), and high temperatures (60–70◦C),
besides a higher fermentative ability and enzymatic activity. An
adaptation at pH 5.2 for 2 h was shown for strains of B. brevis
against subsequent exposure to pH 2–5, bile (0.2–1.0%), H2O2
(100–1,000 ppm) and during storage at different temperatures
(Maus and Ingham, 2003). Sub-lethal H2O2 treatments were
shown to be beneficial to increase cell resistance to oxidative
stress by certain B. longum and B. lactis strains during production
and storage of probiotic foods (Oberg et al., 2011). Salt
pretreatment resulted in an increased tolerance to freeze-thawing
cycles or lethal heat stress in strains of B. adolescentis (Schmidt
and Zink, 2000). The effects of stress pretreatments on enhanced
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stress tolerance of bifidobacteria and other probiotic bacteria
have been reviewed by Sánchez et al. (2013), Nguyen et al. (2015)
and Gaucher et al. (2019).
Drying Processes
Drying technology, which leads to anhydrobiosis, the state at
which an organism stops its vital functions temporarily, is the
oldest method used to improve probiotic stability, allowing them
tomaintain viability and their beneficial action over a long period
of time (Broeckx et al., 2016; Marcial-Coba et al., 2019a; Cassani
et al., 2020). Dehydration of bacteria can be achieved by the
application of different methods, namely freeze-drying, spray-
drying, vacuum-drying, and fluidized-bed drying, the decision
on which to select being based on industrial scale-up and the
cost-effectiveness parameters (Marcial-Coba et al., 2019a). As
previously mentioned, it is generally acknowledged that each
drying process poses stress to bacteria and to some extent causes
inactivation due to the bacterial damage that can be caused
by freezing and thawing (Broeckx et al., 2016; Foerest and
Santivarangkna, 2016; Min et al., 2018). Cryopreservation has
several disadvantages from a commercial point of view, namely
the need for subzero transportation and storage temperatures,
and thus high energy costs (Broeckx et al., 2016). The drying
process implies the removal of intracellular water that causes a
mechanical stress on the bacterial membrane altering its plasticity
and desiccation enhances the contact of bacterial surfaces with
oxygen molecules, inducing the intracellular accumulation of
reactive oxygen species which may lead to damage in bacteria
macromolecules such as proteins, DNA, or lipids (Foerest and
Santivarangkna, 2016;Marcial-Coba et al., 2019a). Based on these
facts, the decision of drying bacteria suspension needs to be
carefully optimized.
Freeze-drying is one of the most used processes known to
dry bacteria while keeping their viability over long periods of
time (Chávez and Ledeboer, 2007; Marcial-Coba et al., 2019a).
However, its costs have hindered its use in large-scale processes
(Chávez and Ledeboer, 2007). Freeze-drying is a process
involving freezing and water removal by sublimation under high
vacuum (Barbosa et al., 2015; Cassani et al., 2020). Briefly, it
consists in three steps: (i) freezing where the extracellular ice
crystal formed can lead to bacterial damage, due to chemical and
osmotic injuries (Broeckx et al., 2016); (ii) primary dehydration
(sublimation), and (iii) secondary dehydration (desorption).
Drying steps affect bacterial integrity, by the water removal
from the cells, leading to a negative impact on the structure
of sensitive proteins, cell wall and the physical state of the
lipid membranes. These changes can also lead to a decrease in
metabolic activity, and consequently, it may lead to a decrease
in the viability of bacteria (Cassani et al., 2020). Nevertheless,
freeze-drying is a preferred dryingmethod for thermally sensitive
bacteria, as it keeps their survival at a reasonably high level
(Goderska, 2012).
Spray-drying is the most popular and widely studied
alternative to freeze-drying due to its easiness to operate and
scale-up. This technique is cost-effective, 4–7 times cheaper and
efficient in the preservation of probiotic viability during and after
drying when compared to freeze-drying (Chávez and Ledeboer,
2007). Basically, spray-drying consists in a process in which
the bacterial suspensions are atomized into droplets in a drying
chamber where a controlled flow of hot air at temperatures up
to 200◦C is found, producing dry spherical powder particles,
enabling the dehydration of large amounts of liquid feed cultures
in a short period of time (Broeckx et al., 2016; Cassani et al.,
2020). However, the continuous exposure to oxygen and heat
stress generated during the desiccation process challenge the
microbial survival and constitute some drawbacks of bacterial
drying by spray-drying (Chávez and Ledeboer, 2007; Broeckx
et al., 2016; Marcial-Coba et al., 2019a).
Chávez and Ledeboer (2007) studied the optimization of
formulation and process to enhance storage survival of B. lactis
BB-12, testing different carrier materials and combinations,
namely, skim milk powder (SMP), SMP combined with Arabic
gum, SMP combined with maltodextrin (MD), SMP combined
with trehalose dihydrate, soy protein isolate (SPI), SPI combined
with MD, SPI combined with lactose and SPI combined with
sucrose. In all combinations, the ration protein: carbohydrate
was 1:1. They also tested different drying processes: freeze-
drying, spray-drying and a two-step drying process (first spray-
drying followed by vacuum-drying). The authors demonstrated
that spray-drying (only) fails in terms of bifidobacteria viability
maintenance during storage (after 1 month only 0.005% of
bacteria survival was achieved). However, with the two-step
drying process, the number of viable bacteria after 2 months of
accelerated storage was similar to those obtained by freeze-drying
(5% of survival). This result suggests that the two-step drying
process seems to be an alternative to freeze-drying to produce
viable probiotics. Moreover, this alternative is estimated to be 3
times cheaper than freeze-drying. Taking into consideration the
previous results, the authors also studied the effect of different
carrier materials on the viability of bacteria, using the two-
step drying process. After the two-step drying, bifidobacteria
survival was between 8 and 100% over 3 months of accelerated
storage (30◦C) and the best matrices were SPI with lactose and
SMP with Arabic gum, with survival higher than 50% after 3
months. On the other hand, the poor matrices for the stability of
bacteria were SPI with sucrose, SMP withMD and with trehalose,
obtaining survival percentage of <1% (Chávez and Ledeboer,
2007).
Bifidobacterium crudilactis FR62/b/3 was considered a new
bifidobacteria strain isolated from raw milk and raw milk cheese.
Tanimomo et al. (2016) studied the large-scale culture of this
strain and its stability in a dry formulation using as protective
agents: betaine, monosodium glutamate, sorbitol, sucrose, and
trehalose. They showed that the protective agents tested had little
impact on cell viability prior to freeze-drying. However, after
the freeze-drying process, the maximum survival rate obtained
was 80.5% when sorbitol was used as protective agent, compared
to 10.5% for control (bacteria dried in PBS). After 6 months
of storage, the viable cell numbers were stabilized with sorbitol
and sucrose, providing the most significant protection of survival
rate at 4 and 23◦C. Nevertheless, sucrose exhibited a significant
preservation level during storage, however, this protectant was
less efficient during freeze-drying. Therefore, these findings
indicated that only sorbitol could be used as a protectant for
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freeze-drying and storage (4 and 23◦C) of B. crudilactis FR62/b/3
(Tanimomo et al., 2016).
Several studies have confirmed that bifidobacteria are very
sensitive to spray-drying and reveal superior survival rates when
freeze-drying using different protective agents is applied (Chávez
and Ledeboer, 2007; Wong et al., 2010; Tanimomo et al., 2016).
Based on these findings, the freeze-drying process seems to be
a better method for stabilization and storage of Bifidobacterium
spp. Celik and O’Sullivan (2013) studied the development of
a freeze-drying protocol for bifidobacteria with different stress
tolerances: B. animalis spp. lactis BB-12, the most stress-adapted
bacteria, and B. longum DJO10A described as a strain with
a high sensitivity to stress factors such as temperature, water
activity, and atmosphere (Celik and O’Sullivan, 2013). They
studied different cryoprotective media and they showed that
the highest recovery rate was obtained with a combination
of sodium phosphate buffer with dried skim milk (5%) and
trehalose (4%).
Chen et al. (2019) designed and optimized the cryoprotectant
for B. bifidum BB01 survival enhancement. They used different
cryoprotectants and evaluated the survival rate and viable cell
numbers per unit weight of the resulting freeze-dried powder.
The results suggested that the best cryoprotectant for B. bifidum
was xylooligosaccharides with the survival rate and the viable cell
numbers per unit weight of powder were around 90% and 11
logs, respectively (Chen et al., 2019). Another study using freeze-
drying with Bifidobacterium spp. was described by Peirotén
et al. (2019). They explored the growth of nine bifidobacterial
strains (B. bifidum, B. longum, B. breve, B. pseudocatenulatum,
B. adolescentis, B. animalis) in milk, and their survival to freeze-
drying and cold storage; a model cheese with two selected
bifidobacterial strains as adjunct cultures was then assessed. As
reported previously by Celik and O’Sullivan (2013), B. animalis
BB-12 was themost stable strain during freeze-drying and storage
(Peirotén et al., 2019). The authors compared freezing at −80◦C
using 5% glycerol as cryoprotectant and freeze-drying using 10%
of skim milk as a protective medium. In terms of ability to
grow in milk, seven out of the nine studied strains grew in milk
without any added growth factor, and four of these registered an
increase of 1–2 log cycles. Concerning the viability of bacteria in
dairy products during cold storage, B. animalis BB-12 showed its
high stability under refrigeration, whereas B. bifidum INIA P826,
B. longum BB536, B. infantis INIA P737 and B. breve INIA P712
were more unstable registering a >1 log cycle reduction upon
14 days of storage. This reduction of viability of bifidobacterial
strains could be related to their strictly anaerobic conditions
and redox potential during refrigeration (Peirotén et al., 2019).
Therefore, different protective strategies like encapsulation have
been explored and proposed as a solution for improvement
of probiotics.
Microencapsulation
Over the past years, research has focused on alternative strategies
to probiotics drying, in order to improve the survival, stability,
and delivery of probiotics. Encapsulation has been highlighted
as one such solution since it is known to enhance stability,
facilitate handling, and storage of probiotics cultures, protecting
them from oxygen and gastrointestinal tract conditions (Terpou
et al., 2019). Basically, encapsulation of probiotics involves the
immobilization and/or coating of bacteria using several materials
such as polysaccharides (alginates, gums, chitosan, starch, k-
carrageenan, pectin), proteins (milk protein, gelatin), and fats
(Marcial-Coba et al., 2019a; Terpou et al., 2019). Sometimes, it
can also be used coupled to freeze-drying, improving the stability
and storage of probiotics, as described by Heidebach et al.
(2010) who demonstrated the improvement of encapsulation
on the survival of freeze-dried Bifidobacterium BB-12 during
storage for up to 90 days. They showed that co-encapsulation
of prebiotic resistant starch corns had a negative influence on
the physical barrier of the protein matrix, leading to a decrease
of the protective effect of the probiotic (Heidebach et al., 2010).
Thantsha et al. (2014) used poly-(vinylpyrrolidone)-poly-(vinyl
acetate-co-crotonic acid) for encapsulation of B. lactis Bb12 and
B. longum Bb46 under supercritical conditions. They described
that microparticles were able to protect the bacteria in simulated
gastrointestinal fluids as well as to improve the lifetime of
storage for 12 weeks at 30◦C. Wang et al. (2014) reported
on the entrapment of B. adolescentis ATCC 15703 preparing
microcapsules using 10% of chickpea protein isolates cross-
linked with 0.20% of genipin, or in the presence of 0.10% of
alginate. Their findings suggested that chickpea protein-alginate
capsules offered a suitable probiotics protection against acid
conditions and indicated that such capsules could serve as a
suitable probiotic carrier for food applications.
The encapsulation method has an important role in the
survival of probiotics, offering protection against unfavorable
environmental conditions and allowing for their controlled
release under intestinal conditions (Terpou et al., 2019). There
are several methods available for the encapsulation of probiotics,
such as spray-drying, freeze-drying, extrusion, emulsion, and
ionotropic gelation (Table 2).
Spray-drying is also a common method for probiotic
encapsulation, where an emulsion or a suspension of the
probiotic and the encapsulating agents are atomized in a hot air-
drying chamber, resulting in fast evaporation of water. de Castro-
Cislaghi et al. (2012) and Fritzen-Freire et al. (2013) encapsulated
B. animalis BB-12 using spray-drying. Both studies obtained
microcapsules with a higher viability and encapsulation yield
after spray-drying, and encapsulated bacteria remained viable
and stable during a long period of time and were able to resist
simulated gastrointestinal conditions.
Freeze-drying can be used as an encapsulation method
but also as a method to improve the probiotic microcapsules
storage. Bhat et al. (2015) were able to immobilize bifidobacteria
strains (B. longum and B. breve) directly on poly-γ-glutamic
acid (γ-PGA) by freeze-drying and then incorporated these
microparticles into fruit juice. They observed that both strains
were protected by γ-PGA, surviving in simulated gastric juice
with a slight reduction (<0.5 logs), whereas free bacteria died
after 2 h. Findings indicate that γ-PGA may be used to protect
gastro-sensitive probiotics, contributing to probiotics increased
survival as they pass through the harsh gastrointestinal tract.
In many cases, Bifidobacterium spp. are first encapsulated in
a matrix and then microparticles are freeze-dried in order
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TABLE 2 | Methods and materials for microencapsulation of Bifidobacterium spp.
Method Microorganisms Materials References
Spray-drying B. animalis BB-12 Whey de Castro-Cislaghi et al., 2012
B. bifidum BB01 Na-Alginate and chitosan Chen et al., 2017
B. animalis BB-12 Skim milk and prebiotics Fritzen-Freire et al., 2012
Freeze-drying B. animalis BB-12 Gelatin and gum arabic Marques da Silva et al., 2018
B. longum NCIMB 8809 B. breve
NCIMB 8807
Poly-γ-glutamine acid Bhat et al., 2015
B. longum LMG13197 Vegetal BM 297 ATO Amakiri and Thantsha, 2016
Extrusion B. animalis BB-12
Lactobacillus spp.
Na-Alginate Sousa et al., 2015
B. pseudocatenulatum G4 Na- Alginate
Chitosan
Kamalian et al., 2014
B. adolescentis ATCC 15703 Legume protein
isolate-alginate
Khan et al., 2013
B. adolescentis ATCC 15703 Pea protein isolate- alginate Klemmer et al., 2011
B. animalis BB-12 Alginate
Alginate-L-cysteine
Rebecca et al., 2015
Emulsion B. adolescentis ATCC 15703 Chickpea protein-alginate Wang et al., 2014
Emulsification/internal gelation B. bifidum F-35 Alginate Zou et al., 2011
B. longum DD98 Alginate
Alginate coated
with chitosan
Ji et al., 2019
B. animalis BB-12 Na-alginate Holkem et al., 2017
B. animalis PBS075 Na Alginate D’Orazio et al., 2015
to enhance probiotics survival in simulated gastrointestinal
fluids and storage. Amakiri and Thantsha (2016) encapsulated
B. longum LMG13197 using lipid microparticles and freeze-
drying and showed that lipid matrix combined with inulin
was able to protect probiotics from gastrointestinal fluids and
enhance the storage compared to unencapsulated probiotics.
Moreover, freeze-drying offered an increased protection to
bacteria-loaded lipid microparticles, protecting the probiotics
from gastric acid and enabling their release at sufficiently high
viable cell numbers into the simulated intestinal fluid, allowing
them to efficiently colonize the colon.
Microencapsulation by extrusion is the major process for
the production of probiotic microcapsules. The probiotic-
matrix-mixture is mixed homogeneously and then the mixture
is extruded through a syringe needle at high pressure to
produce droplets, which will solidify by gelation or formation
of a membrane on their surface (Rebecca et al., 2015;
Marcial-Coba et al., 2019a). The obtained capsule size is
dependent on the viscosity of the encapsulation material,
the nozzle diameter and the droplet height (Rebecca et al.,
2015). However, these capsules are generally large (0.1–
10mm), wet and unstable during long-term storage (Rebecca
et al., 2015). Extrusion was used to encapsulate B. animalis
BB-12 in plain alginate or alginate supplemented with L-
cysteine-HCl and stored at different temperatures for a
period of up to 6 months. The findings showed that the
encapsulation was only effective in promoting protection at
freezing temperatures, independently of the strain sensitivity
(Rebecca et al., 2015).
Emulsification is another common technique for probiotics
encapsulation; it consists of a mixture of two immiscible
liquids in which one of them is in small droplets within
another liquid to form a stable mixture (Costa et al., 2014;
Rebecca et al., 2015). The size of microcapsules produced
by emulsification ranges from 25 to 2,000µm depending
on the variation of stirring speed, mixer type, and type of
emulsifying agents, and the water/oil ratio (Sarao and Arora,
2017). The difficulty to obtain uniformly shaped microcapsules
between batches is the major drawback of the emulsification
technique (Marcial-Coba et al., 2019a). Ji et al. (2019) showed
that microencapsulation using emulsification/internal gelation
provided an enhancement of B. longum DD98 protection;
however, an unexpected decrease in the viability of bacteria
loaded into alginate microcapsules was observed when exposed
to simulated gastrointestinal conditions, while B. longum viability
was maintained using microcapsules coated with chitosan. These
findings differed from the results of Yeung et al. (2016) who
encapsulated B. longum by extrusion and chitosan coating, yet
when these were exposed to simulated gastrointestinal fluids, the
protective effect was not as obvious as that reported by Ji et al.
(2019).
Despite the several microencapsulation methods employed
to improve probiotic stability and viability further research
is required on the design and optimization of appropriate
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technologies to encapsulate probiotic cells. Key factors that
remain true challenges include the probiotic strain type and
the processing conditions, namely temperature, oxygen stress,
as well as encapsulation material; the probiotic cell size and
its concentration can have a direct influence on capsule size
which may have negative effect on the sensory proprieties of food
(Terpou et al., 2019).
Akkermansia
Among the few potential NGPs, Akkermansia muciniphila,
the only cultured member of Verrucomicrobia phylum that
abundantly colonizes the human gut (Derrien et al., 2010), is
regarded as the most promising candidate. However, sensitivity
to challenging factors such as molecular oxygen, low pH levels
found in gastric environment, and bile salts, demand the
development of a technological logistic pathway that enables
the survival of this anaerobic probiotic candidate. As all other
anaerobic bacteria, oxygen levels, and redox potential are a major
issue that can lead to a loss in cell viability. Curiously, the
idea that A. muciniphila is a strict anaerobe (Derrien et al.,
2004) was challenged recently when the NGP was proposed to
be aerotolerant in nature (Machado et al., 2019). Indeed, when
exposed to an aerobic environment in temperatures ranging from
4 to 37◦C, A. muciniphila exhibited a high oxygen tolerance
up to 72 h, albeit a higher oxygen tolerance was exhibited at
4◦C. The manifested oxygen tolerance was previously argued
when A. muciniphila remained metabolically active even in the
presence of nanomolar concentrations of oxygen (Ouwerkerk
et al., 2016). This intrinsic oxygen tolerance A. muciniphila
encourages the future implementation of a wider range of
handling protocols, which facilitates large-scale propagation
during technological investigations. Interestingly, the potential
temperature effect associated with an oxygen exposure can be
further assessed in data pertaining to the strategies explored to
successfully protect and deliver viable functional A. muciniphila
cells, which have been focused mainly on encapsulation
systems. According to Marcial-Coba et al. (2018, 2019b), the
stability displayed when assessing different microencapsulation
formulations was higher at refrigeration temperatures (4◦C).
The researchers described two microencapsulation protocols
based on conventional extrusion mechanism [ionotropic cross-
linking biopolymer in hardening solution containing cations
like Ca2+ (de Prisco et al., 2015)] using A. muciniphila strain
DSM22959. In the first study the authors reported the application
of xanthan/gellan gum polymeric matrix for cell immobilization
with a subsequent freeze-drying step, in which they used various
combinations of cryoprotective compounds (Marcial-Coba et al.,
2018). The use of higher sugar cryoprotectants [sweetener agave
syrup 10 % (w/v)] combined with xanthan/gellan gum matrix,
in the form of freeze-dried microcapsules, provided a higher
encapsulation efficiency (EE) (76.2%) when compared with the
other cryoprotectants. Furthermore, this formulation was able to
enhance A. muciniphila survival during in vitro GIT conditions
at both fasted (gastric phase pH 2) and fed (gastric phase pH 4)
state, when compared to free cells under the same conditions.
Later, the same authors analyzed the efficacy of dark chocolate
as a carrier for A. muciniphila that translated into an efficient
protection during simulated gastric transit (pH 3) (Marcial-
Coba et al., 2019b). These results differ from the first report
of encapsulation of A. muciniphila cells given by van der Ark
et al. (2017), in which the bacterial culture was immobilized
in a water-in-oil- in water double emulsion. The generated EE
was high (97.5%), and although survival during GIT passage
was enhanced relative to free cells, the viability during only
72 h of anaerobic storage at 4◦C exhibited a sharp reduction.
Indeed, the implementation of physical protective systems, such
as encapsulation, are required to mitigate any viability losses
A. muciniphila might suffer during prolonged storage periods
and even more so during GIT passage, thereby guaranteeing
its biofunctionality. Despite the major differences that were
found between aerobic and anaerobic storage, A. muciniphila
microencapsulation constitutes a promising strategy to provide
stability during ideally refrigerated storage. Notwithstanding a
greater focus should be given for protection in the hostile GIT
passage conditions and ideally, other delivery/protection vehicles
should be investigated.
Conversely, the A. muciniphila cell propagation requires
specific culture components, such as the addition of mucin
(animal-derived) which raises concerns for human consumption.
In this sense, a synthetic media was recently developed that
respected safety clinical parameters for human administration
allowing large scale cultivation approaches (Plovier et al., 2016).
The same authors also identified, Amuc_1100, a surface protein
that recapitulates the key health effects of the whole live
A.muciniphila cell on the host, thereby enabling the development
of novel safe therapeutics. Interestingly, it was demonstrated
in a recent transcriptomic analysis study, that this bacterium
growth in mucin-depleted conditions upregulated most genes
involved in energy metabolic pathways and glycolysis, as well
as genes encoding the expression of several proteins among
which Amuc_1100 (Shin et al., 2019). These results were further
substantiated in vivo with the administration of A. muciniphila
grown in such conditions to obese mice, in which an efficient
reduction in fat mass and improvement of gut permeability was
observed, providing new data that enables the translation for
human therapeutics. Furthermore, progress was already made
relative to a potentially scalable preservation and preparation
protocol for the use of viable A. muciniphila in therapeutic
interventions (Ouwerkerk et al., 2017). Such efforts will allow
the use of this anaerobic NGP as an interventional therapeutic
tool in cardiometabolic diseases, just as in the first A. muciniphila
exploratory study which used heat-inactivated bacterium to
demonstrate its positive influence on various cardiovascular risk
factors (Depommier et al., 2019).
Faecalibacterium
As mentioned before Faecalibacterium prausnitzii has become
one of the most promising commensal and ubiquitous bacteria
among NGPs candidates due to its positive impact on the
microbiota and the host’s health (Benevides et al., 2017). Despite
multiple health promoting-effects, F. prausnitzii is extremely
sensitive to oxygen since exposure to ambient air for more
than 2min inhibits all subsequent bacterial growth (Duncan
et al., 2002). However, it has been found that it can endure
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low levels of oxygen by adherence to the gut mucosa where
oxygen diffuses from epithelial cells, through an extracellular
electron shuttle of flavins and thiols to transfer electrons to
oxygen (Khan et al., 2012). Based on the previous finding,
it was demonstrated that F. prausnitzii was able to stay alive
in aerobic environment for 24 h when formulated with the
antioxidants cysteine and riboflavin plus the cryoprotectant
inulin. Improved formulations were obtained by addition of
the bulking agents corn starch and wheat bran, easing the
handling (Khan et al., 2014). Recently, Bircher et al. (2018a)
investigated cryopreservation (at −80◦C) and freeze-drying
survival and storage stability (4◦C for 3 months) of some strict
gut anaerobes, including F. prausnitzii. Interestingly, they verified
that F. prausnitzii had increased viability when preserved by
freeze-drying using sucrose and inulin as protectant agents.
In this alignment, Allouche et al. (2018) developed probiotic
tablets by direct compression of a mixture of certain excipients
with F. prausnitzii previously lyophilized with sucrose, that
displayed high stability during 28 days of anaerobic storage.
Nevertheless, these researchers highlighted the need to find
alternatives to anaerobic storage as well as the urgency to develop
an optimal coating to protect bacteria against gastric acidity
(Allouche et al., 2018). Thus, to reduce or eliminate the presence
of oxygen in technological processes such as formulation or
freeze drying, the employment of antioxidants, cryoprotectants,
and prebiotic agents is of extreme importance in order to
enhance the viability and stability during aerobic storage of NGPs
(Almeida et al., 2019).
Other Anaerobic Microorganisms
The inherent novelty to NGPs entails little data concerning the
production of delivery vehicles of commensal anaerobic bacteria,
as well as their viability and stability during storage, considering
that these parameters are modified with the probiotic strain
involved (O’Toole et al., 2017). In this context, cryopreservation,
and freeze-drying techniques have also been explored as
strategies to enhance the viability and stability of commensal
anaerobic bacteria (Bircher et al., 2018a,b). Indeed, Bircher
and coworkers investigated cryopreservation (at −80◦C) and
lyophilization survival and storage stability (4◦C for 3 months)
of the strict anaerobic gut bacteria Bacteroides thetaiotaomicron,
F. prausnitzii, Roseburia intestinalis,Anaerostipes caccae, E. hallii,
and Blautia obeum. In this study, researchers concluded that
B. obeum, R. intestinalis, E. hallii, and A. caccae shoud be
preserved by cryopreservation in glycerol, sucrose, and inulin
solution and only sucrose and inulin for B. thetaiotaomicron.
In another study this same research group evaluated the impact
of two cryoprotectives, glycerol (15% v/v) and inulin (5% w/v)
alone and in combination, in preserving SCFAs formation and
recovery of major gut butyrate-producing bacteria (Roseburia
spp., Eubacterium rectale, F. prausnitzii, and E. hallii) during
cryopreservation for 3 months at −80◦C. Results revealed that
gut butyrate producers can be well-preserved with glycerol and
inulin during frozen storage (Bircher et al., 2018b).
Moreover, encapsulation techniques have been employed
to develop delivery systems containing commensal gut
anaerobic bacteria. In fact, Eeckhaut and colleagues developed
hydroxypropylmethylcellulose capsules containing commensal
anaerobic bacterium B. pullicaecorum, which displayed a
high stability during storage (a reduction of only 1 log after
7 months was observed). It is important to note that in this
study B. pullicaecorum was anaerobically lyophilized in horse
serum supplemented with trehalose and cysteine, before
capsules filling (Eeckhaut et al., 2014). Later, Boesmans et al.
(2018), using a similar encapsulation technique, showed that
hydroxypropylmethylcellulose capsules containing a freeze-
dried culture of B. pullicaecorum preserved its viability over an
8-month storage period at 4◦C. Furthermore, they verified that
these capsules were safe and well-tolerated by the human host,
without causing disruptive alterations in the composition or
metabolic activity of health-associated microbiota (Boesmans
et al., 2018). Still in the context of strict anaerobic bacteria
encapsulation, Cui (2017) showed that double encapsulation
of C. minuta freeze dried powder by alginate-based extrusion
provided a high viability of C. minuta during the process of
encapsulation, as well as, after in vitro gastrointestinal tract
passage with good stability during storage for at least 2 months.
Furthermore, this researcher incorporated C. minuta beads in
coconut jelly in order to develop a non-dairy probiotic food
product, having verified that C. minuta beads in coconut jelly




Certain human commensals, such as those discussed above,
which are particularly abundant in healthy individuals compared
to patients in various diseases groups, are already being sought
to be used to address and mitigate some clinical situations.
Other novel microorganisms may be expected to emerge in
the next years from the continuous efforts made to investigate
the role of the human microbiome. These developments will
present substantial challenges for the scientific community
and for the interested industry stakeholders. Most of the
potential NGPs (or potential live biotherapeutics) identified so
far, are difficult to cultivate or to obtain in high numbers
and to maintain viable for long periods of time, mainly
due to their nutritional requirements and/or strict anaerobic
character. In order to enable intervention performance in
clinical trials, biomass has to be produced in high amounts
(as economically as possible), be adequately stable and safe for
human usage. Bifidobacteria are human anaerobic commensals
that are supported by a long tradition of being used in
the food and supplement industries, but still only a few
technological robust strains are commonly used. Continuous
efforts are being made to obtain stable and functional products
containing bifidobacteria (as other probiotics). In this context,
the use of sublethal stresses and of microencapsulation have
been two of the most investigated strategies and with some
promising results. The experience gathered in the studies with
bifidobacteria may be applied and be used as a basis for the
development of other anerobic commensals products. In fact,
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org 16 June 2020 | Volume 8 | Article 550
Andrade et al. Commensal Obligate Anaerobic Bacteria and Health
some preliminary promising studies of microencapsulation of
Akkermansia strains have already been reported. The tailored
strategies used to produce and stabilize the different strains,
may alter their biological functionality, hence, research on
identification of markers/ways to evaluate themaintenance of cell
functionality upon processing and product manufacture is also
highly warranted.
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